Virological outcome at week 48 of three recommended first-line regimens using ultrasensitive viral load and plasma drug assay | Zendy

Charlotte Charpentier | Zendy; M. Choquet | Zendy; Véronique Joly | Zendy; P. Yéni | Zendy; Benoît Visseaux | Zendy; Marion Caséris | Zendy; Françoise BrunVézinet | Zendy; Yazdan Yazdanpanah | Zendy; Gilles Peytavin | Zendy; Diane Descamps | Zendy; R. Landman | Zendy

Open Access

Virological outcome at week 48 of three recommended first-line regimens using ultrasensitive viral load and plasma drug assay

Author(s) -

Charlotte Charpentier,

M. Choquet,

Véronique Joly,

P. Yéni,

Benoît Visseaux,

Marion Caséris,

Françoise BrunVézinet,

Yazdan Yazdanpanah,

Gilles Peytavin,

Diane Descamps,

R. Landman

Publication year - 2014

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dku211

Subject(s) - darunavir , efavirenz , atazanavir , ritonavir , medicine , regimen , emtricitabine , viral load , virology , therapeutic drug monitoring , pharmacology , pharmacokinetics , human immunodeficiency virus (hiv) , antiretroviral therapy

To describe the virological and pharmacological outcomes of three different recommended once-daily first-line regimens in a cross-sectional analysis within an observational cohort using ultra-sensitive HIV quantification.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research